Shanghai Henlius Biotech, Inc. (2696.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
Innov Tower (Capitaland Building)
Shanghai, 200233
China
Phone
86 21 3339 5800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
3515
First IPO Date
September 25, 2019
| Name | Title | Pay | Year Born |
| Jun Zhu | Chief Executive Officer & Executive Director | 12.74M | 1979 |
| Shi-Kau Liu | Co-founder & Head of Strategy Advisory Committee | 7.19M | 1964 |
| Ping Cao | Senior VP & Chief Business Development Officer | 0 | 1972 |
| Jijun Yuan | Chief Scientific Officer | 0 | 1978 |
| Wei-Dong Jiang | Co-Founder & Co-Head of Innovative Advisory Committee | 0 | 1963 |
| Wallis Zeng | Vice President of Sales & Oncology Business Unit | 0 | N/A |
| Xinjun Guo | Senior Vice President | 0 | 1972 |
| Yingbo Mao | Vice President & Chief Financial Officer | 0 | 1979 |
| Zhiyong Liu | GM of Production & Employee Representative Supervisor | 0 | 1973 |
| Wei Huang | President | 0 | 1968 |
| Miaojie Chen | Vice President of Legal & Compliance | 0 | N/A |
| Huang Wei | President | 0 | 1968 |
| Yan Wang | GM of Public Relations, Joint Company Secretary & Board Secretary | 0 | 1988 |
| Junhua Li | Senior Vice President & Chief Human Resources Officer | 0 | 1976 |
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.